Acurx Pharmaceuticals, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Acurx Pharmaceuticals, Inc. (ACXP) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $1.86 million as of 2025-03-31, per its 10-Q filed 2025-05-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2025-05-12
- 2025-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $1.86M.
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $2.17M.
- 2024-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $2.52M.
- 2024-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $2.86M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2025-03-31 | $1.86M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $2.17M 10-K · filed 2025-03-17 |
| 2024-09-30 | $2.52M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.86M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.77M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.46M 10-K · filed 2024-03-15 |
| 2023-09-30 | $3.29M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $4.13M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $4.82M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $4.24M 10-K · filed 2023-03-15 |
| 2022-09-30 | $4.94M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.64M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $6.27M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $6.73M 10-K · filed 2022-03-16 |
| 2021-09-30 | $7.40M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $2.18M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |